Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
24.28
-0.82 (-3.25%)
At close: Apr 28, 2026, 4:00 PM EDT
24.29
+0.02 (0.06%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Septerna Employees
Septerna had 130 employees as of December 31, 2025. The number of employees increased by 55 or 73.33% compared to the previous year.
Employees
130
Change (1Y)
55
Growth (1Y)
73.33%
Revenue / Employee
$353,469
Profits / Employee
-$375,992
Market Cap
1.09B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 55 | 73.33% |
| Dec 31, 2024 | 75 | - | - |
| Sep 30, 2024 | 73 | - | - |
| Jun 30, 2024 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xeris Biopharma Holdings | 435 |
| Pharming Group | 407 |
| UroGen Pharma | 291 |
| KalVista Pharmaceuticals | 275 |
| uniQure | 221 |
| EyePoint | 214 |
| Zenas BioPharma | 167 |
| DBV Technologies | 117 |
SEPN News
- 15 days ago - Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - GlobeNewsWire
- 7 weeks ago - Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Septerna Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Septerna Transcript: Study result - Transcripts
- 2 months ago - Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy - GlobeNewsWire
- 2 months ago - Septerna to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting - GlobeNewsWire